eCite Digital Repository
A randomized trial of high-dose versus conventional-dose cytarabine in consolidation chemotherapy for adult de nova acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine
Citation
Bradstock, KF and Mathews, JP and Lowenthal, RM and Baxter, H and Catalano, J and Brighton, T and Gill, D and Elliadis, P and Joshua, D and Cannell, P and Schwarer, AP and Durrant, S and Gillett, A and Koutts, J and Taylor, K and Bashford, J and Arthur, C and Enno, A and Dunlop, L and Szer, J and Leahy, M and Juneja, S and Young, GAR, A randomized trial of high-dose versus conventional-dose cytarabine in consolidation chemotherapy for adult de nova acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine, Blood, 105, (2) pp. 481-488. ISSN 0006-4971 (2005) [Refereed Article]
DOI: doi:10.1182/blood-2004-01-0326
Abstract
The value of administering sequential courses of chemotherapy containing high-dose cytarabine in both induction and consolidation therapy for acute myeloid leukemia (AML) has not been assessed in a prospective randomized trial. Two hundred ninety-two AML patients aged 15 to 60 years were enrolled in the Australasian Leukaemia and Lymphoma Group (ALLG) AML trial number 7 (M7) protocol to evaluate this question. All received induction therapy with the ICE protocol (idarubicin 9 mg/m 2 × 3; cytarabine 3 g/m 2 twice a day on days 1, 3, 5, 7; etoposide 75 mg/m 2 × 7). Complete remission was achieved in 234 (80%) patients. Two hundred two patients in remission were then randomized to either a further identical cycle of ICE or 2 attenuated courses (cytarabine 100 mg/m 2 daily × 5, idarubicin × 2, etoposide × 5 [IcE]). ICE consolidation therapy was more toxic than IcE, however, the treatment-related death rate was not significantly different. There was no difference between the 2 consolidation arms for relapse-free survival at 3 years (49% for ICE vs 46% for IcE; P = .66), survival following randomization (61% vs 62%; P = .91), or the cumulative incidence of relapse (43% vs 51%; P = .31), and there was no difference within cytogenetic risk groups. Intensive induction chemotherapy incorporating high-dose cytarabine results in high complete remission rates, but further intensive consolidation treatment does not appear to confer additional benefit. © 2005 by The American Society of Hematology.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Research Division: | Medical and Health Sciences |
| Research Group: | Oncology and Carcinogenesis |
| Research Field: | Oncology and Carcinogenesis not elsewhere classified |
| Objective Division: | Health |
| Objective Group: | Clinical Health (Organs, Diseases and Abnormal Conditions) |
| Objective Field: | Cancer and Related Disorders |
| Author: | Lowenthal, RM (Professor Ray Lowenthal) |
| ID Code: | 36157 |
| Year Published: | 2005 |
| Web of Science® Times Cited: | 61 |
| Deposited By: | Medicine (Discipline) |
| Deposited On: | 2005-08-01 |
| Last Modified: | 2012-03-01 |
| Downloads: | 0 |
Repository Staff Only: item control page